This highlights RAAS as a critical mediator at the intersection of renal, cardiovascular and metabolic disease, and underscores the broader therapeutic relevance of mineralocorticoid receptor antagonism in addressing complications of obesity and diabetes. This evidence concerns the gene NR3C2 and obesity due to melanocortin 4 receptor deficiency.